AbbVie vs Dr Reddys Laboratories
ABBV and RDY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABBV and RDY compare
AbbVie grew revenue faster over the last twelve months (10.4% versus 3.2% for Dr Reddys Laboratories).
Dr Reddys Laboratories keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 9.8% at AbbVie.
AbbVie pays a dividend yielding 2.3%; Dr Reddys Laboratories does not pay one.
AbbVie scores higher on the StockData Score (10 against 7 for Dr Reddys Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABBV | RDY |
|---|---|---|
| Size and price | ||
| Market cap | $521B | – |
| Share price | $294.89 | $14.17 |
| Change, 1 year | 31.0% | 5.7% |
| Change, 5 years | 152% | 11.8% |
| Beta (5Y) | 0.29 | 0.37 |
| Employees | 57K | – |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 2 | 4 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 83.3× | – |
| P/S | 8.1× | – |
| EV/EBITDA | 34.7× | – |
| P/FCF | 28.6× | – |
| FCF yield | 3.5% | – |
| Fair value | $152.33 | – |
| Margin of safety | −93.6% | – |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | 3.2% |
| Revenue growth, 5Y average | 6.0% | 12.1% (better) |
| Net income growth (TTM) | 67.7% (better) | −24.2% |
| EPS growth (TTM) | 68.6% (better) | −24.1% |
| EPS growth, 5Y average | −2.8% | 19.9% (better) |
| Profitability | ||
| Gross margin | 71.5% (better) | 52.8% |
| Operating margin | 26.2% (better) | 15.0% |
| Net margin | 9.8% | 12.8% (better) |
| FCF margin | 28.3% (better) | 10.0% |
| Return on equity | – | 12.1% |
| Return on invested capital | 20.1% (better) | 9.7% |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Net debt / EBITDA | 3.81 | 0.87 (better) |
| Interest coverage | 5.8× | 13.5× (better) |
| Current ratio | 0.81 | 1.80 (better) |
| Altman Z-score | 2.86 | – |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% | – |
| Payout ratio | 190% | 15.5% |
| Years of dividend growth | 11 (better) | 0 |
| Dividend growth, 5Y average | 6.6% | 9.9% (better) |
| Buyback yield | 0.29% | – |
| Shareholder yield | 2.6% | – |
| Ownership | ||
| Held by institutions | 75.6% | 15.1% |
| Held by insiders | 0.09% | 13.6% |
| Insider net buying, 12 months | −$18.9M | – |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 0.92% | – |
Go deeper
- ABBV stock overview
- ABBV income statement
- ABBV valuation and score
- RDY stock overview
- RDY income statement
- RDY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.